Truist Lowers Centene PT to $35 Despite Stronger PDP, Medicare Advantage Performance

Centene Corporation (NYSE:CNC) is one of the most profitable value stocks to buy according to analysts. On July 28, Truist lowered its price target on Centene to $35 from $42 but maintained a Buy rating on the shares following the company’s Q2 2025 results. Truist noted better performance in Centene’s Prescription Drug Plan/PDP and Medicare Advantage lines of business.

In Q2 2025, the company reported premium and service revenue of $42.5 billion, which contributed to total revenues of $48.7 billion. However, Centene reported an adjusted diluted loss per share of $0.16 for Q2 2025, which missed analyst expectations for a profit, and a GAAP diluted loss per share of $0.51. The Marketplace business also faced a $2.4 billion full-year headwind expected for 2025.

Truist Lowers Centene PT to $35 Despite Stronger PDP, Medicare Advantage Performance

A doctor holding a clipboard in a hospital ward, discussing patient treatment plan with the nurses.

For 2026, Centene aims to reprice 100% of its book to improve profitability and focus on margin over membership. The company is also advocating for greater transparency and earlier data availability to improve market stability.

Centene Corporation (NYSE:CNC) is a healthcare enterprise that provides programs and services to under-insured and uninsured families, and commercial organizations in the US.

While we acknowledge the potential of CNC to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than CNC and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.